Riverview Trust Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Riverview Trust Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10	Closed	-$657	–	625
2024 Q4	$657	Buy	10 +3	+43%	+$201	﹤0.01%	729
2024 Q3	$492	Sell	7 -204	-97%	-$17.1K	﹤0.01%	794
2024 Q2	$17.4K	Hold	211	–	–	0.02%	493
2024 Q1	$18.4K	Buy	+211	New	+$18.9K	0.01%	516
2023 Q4	–	Sell	-211	Closed	-$18.7K	–	157
2023 Q3	$18.7K	Hold	211	–	–	0.02%	415
2023 Q2	$18.3K	Hold	211	–	–	0.02%	399
2023 Q1	$20.5K	Hold	211	–	–	0.02%	338
2022 Q4	$22K	Hold	211	–	–	0.02%	319
2022 Q3	$18K	Hold	211	–	–	0.02%	385
2022 Q2	$17K	Hold	211	–	–	0.01%	433
2022 Q1	$16K	Buy	+211	New	+$17.7K	0.01%	578

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riverview Trust Company's BMRN Position: Q1 2025 in Review

Riverview Trust Company sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 10 shares — an estimated $657 sold.

Riverview Trust Company first reported a position in BMRN in Q1 2022 and held it in 11 quarters. The position peaked at $22K in Q4 2022. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Riverview Trust Company reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Riverview Trust Company sold 10 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $657.
Riverview Trust Company first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 11 quarters.
Riverview Trust Company's BioMarin Pharmaceuticals position peaked at $22K in Q4 2022.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.